BridgeBio Pharma Reaches Analyst Target Price
November 30, 2020 at 08:56 AM EST
In recent trading, shares of BridgeBio Pharma Inc (BBIO) have crossed above the average analyst 12-month target price of $49.12, changing hands for $49.13/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..